Objective-Platelets are important for the development and progression of atherosclerotic lesions. However, relatively little is known about the contribution of platelet signaling to this pathological process. Our recent work identified 2 independent, yet synergistic, signaling pathways that lead to the activation of the small GTPase Rap1; one mediated by the guanine nucleotide exchange factor, CalDAG-GEFI (CDGI), the other by P2Y12, a platelet receptor for adenosine diphosphate and the target of antiplatelet drugs. In this study, we evaluated lesion formation in atherosclerosis-prone lowdensity lipoprotein receptor deficient (Ldlr −/− ) mice lacking CDGI or P2Y12 in hematopoietic cells. Approach and Results-Lethally irradiated Ldlr −/− mice were reconstituted with bone marrow from wild-type (WT), Caldaggef1 −/− (cdgI −/− ), p2y12 −/− , or cdgI −/− p2y12 −/− (double knockout [DKO]) mice and fed a high-fat diet for 12 weeks. Ldlr −/− chimeras deficient for CDGI or P2Y12 developed significantly smaller atherosclerotic lesions in the aortic sinus and in aortas when compared with the Ldlr −/− /WT controls. We also observed a significant reduction in platelet-leukocyte aggregates in blood from hypercholesterolemic Ldlr −/− /cdgI −/− and Ldlr −/− /p2y12 −/− chimeras. Consistently, fewer macrophages and neutrophils were detected in the aortic sinus of Ldlr −/− /cdgI −/− and Ldlr −/− / p2y12 −/− chimeras. Compared with controls, the plaque collagen content was significantly higher in Ldlr −/− chimeras lacking CDGI. Interestingly, no statistically significant additive effects were seen in Ldlr −/− /DKO chimeras when compared with chimeras lacking only CDGI.
A therosclerosis is a chronic inflammatory vascular disease involving various cells, such as vascular cells, leukocytes, and platelets. The presence of circulating activated platelets has been reported in the blood of patients with unstable atherosclerosis, 1,2 stable coronary disease, 3 and hypercholesterolemia. 4 Platelet depletion or blockade of the main platelet adhesion receptors, GPIbα or αIIbβ3, in apolipoprotein E-null (apoE −/− ) mice profoundly reduced leukocyte accumulation in the arterial intima and attenuated atherosclerotic lesion formation. 5 Thus, platelets seem to be a proximal sensor of the vascular injury before the development of atherosclerotic lesions.
Platelet activation has long been postulated to contribute to the development of atherosclerotic plaques although the mechanism by which this might occur is not clear. Activated platelets in blood bind leukocytes mainly via a platelet P-selectin-leukocyte P-selectin glycoprotein ligand-1 interaction 6 and platelet−leukocyte aggregates are well documented in patients and mice with atherosclerosis. 7, 8 Once formed, platelet-leukocyte aggregates promote endothelial cell (EC) activation and EC P-selectin-dependent leukocyte rolling. 9 Indeed, deletion of P-selectin in platelets or ECs leads to significantly impaired early atherosclerotic lesion development in mice. 10, 11 Platelets are also a reservoir for cytokines (eg, CXC chemokine ligand 4, interleukin-1β, CD40L), which can increase vascular permeability and leukocyte arrest/extravasation. 12, 13 Interaction between activated platelets and ECs triggers cytokine secretion (eg, chemokine (C-C motif) ligand 2), increased surface expression of inflammatory adhesion molecules (eg, vascular cell adhesion protein 1), and the release of microvesicles by ECs. 6 The initial platelet tethering depends on the interaction of glycoprotein VI with subendothelial collagen and GPIb-V-IX with von Willebrand factor bound to the surface of activated ECs. 14 After cellular activation, integrin αIIbβ3 is critical for firm adhesion of platelets to the exposed subendothelium and to activated ECs. 15 Studies from our group established a central role for Ca 2+ and diacylglycerol regulated guanine nucleotide exchange factor I (CDGI, RasGRP2) in the inside-out activation of integrins on platelets and neutrophils. [16] [17] [18] CDGI catalyzes the activation of the small GTPase Rap1. In platelets, the Rap1B isoform accounts for ≈90% of the total Rap protein, 19 and its importance in αIIbβ3 activation was demonstrated in studies with Rap1bdeficient mice. 20 Our recent studies identified a 2-pathway model for Rap1-dependent integrin activation downstream of PLC activation in platelets. 21 CDGI is a high-affinity sensor for Ca 2+ , which mediates the rapid but reversible activation of αIIbβ3. 22 In the absence of CDGI, Rap1/integrin activation is delayed but sustained and depends on signaling by protein kinase C and the platelet receptor for adenosine diphosphate (ADP) and P2Y12. 23 Importantly, apoE −/− mice deficient in P2Y12 exhibit reduced plaque formation when on high-fat diet (HFD). 24 Furthermore, treatment of atherosclerotic patients with the P2Y12 inhibitor, clopidogrel, reduced the number of P-selectin-positive platelets and platelet-leukocyte aggregates in blood. 25, 26 In mice, an antiatherogenic effect of clopidogrel was reported by some investigators, 27, 28 whereas others could not reproduce these results. 29, 30 Based on these observations, we hypothesized that platelet Rap1 signaling, mediated by CDGI and P2Y12, contributes to plaque development in atherosclerosis-prone Ldlr −/− mice, and that deletion of CDGI in hematopoietic cells leads to impaired lesion development in hypercholesterolemic Ldlr −/− mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Generation and Characterization of Ldlr −/− Mice Lacking CalDAG-GEFI or P2Y12 in Blood Cells Only
At 4 weeks of age, Ldlr −/− male mice were lethally irradiated and reconstituted with bone marrow from either wild-type (WT), cdgI −/− , p2y12 −/− , or double knockout (DKO; cdgI −/− p2y12 −/− ) mice. After 6 weeks of normal chow diet, leukocyte counts and platelet counts were not significantly different between transplanted animals ( Figure I in the online-only Data Supplement). The mice were then put on HFD for 12 weeks, and the blood lipid levels and platelet activation response were assessed. Total cholesterol, triglyceride, very low-density lipoprotein, high-density lipoprotein, and body weight were similar among all groups after 12 weeks of HFD (Table) . Platelet counts were similar between the different groups of chimeric mice ( Figure 1A) . In response to stimulation of the thrombin receptor, protease-activated receptor 4 (PAR4), or the collagen receptor, glycoprotein VI, platelets from Ldlr −/− /cdgI −/− and Ldlr −/− /p2y12 −/− mice showed reduced P-selectin exposure and integrin activation compared with Ldlr −/− / WT platelets ( Figure 1B ). As expected, agonist-induced platelet activation was abolished in Ldlr −/− /DKO mice ( Figure 1B) .
Platelet adherence to fibrous-cap-derived collagen or the damaged endothelium is a nidus for inflammatory and progenitor cell accumulation at atherosclerotic sites leading to atheroprogression. Therefore, we examined platelet accumulation on a collagen surface under flow. Anticoagulated whole blood from hypercholesterolemic mice was perfused over immobilized collagen at arterial (1200 s -1 ) shear rates. Blood from Ldlr −/− / WT chimeric mice formed 3-dimensional thrombi that stained strongly for surface P-selectin, a marker of platelet activation ( Figures 1C through 1E ). In contrast, thrombus formation at arterial shear rates was almost completely abolished in blood isolated from both Ldlr −/− /cdgI −/− and Ldlr −/− /DKO mice. Small thrombi containing activated (P-selectin-positive) platelets were observed when blood from Ldlr −/− /p2y12 −/− chimeric mice was perfused over collagen. These findings are consistent with our previous work showing significantly impaired adhesion under flow conditions for platelets lacking CDGI or P2Y12. 21 Although integrin activation, and to some extent granule secretion, is dependent on Rap1 signaling, we wanted to directly assess Rap1 activation and determine the effect of cholesterol on platelet sensitivity to activation. When stimulated with the weaker agonist, ADP, platelet aggregation and Rap1 activation were abolished in CdgI −/− or p2y12 −/− platelets, both in the presence and absence of exogenous cholesterol ( Figure 2 ). Interestingly, cholesterol loading of wild-type platelets enhanced ADP-induced Rap1 activation and aggregation and delayed reversibility, with no apparent effect in platelets deficient for CalDAG-GEFI or P2Y12. 
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Reduced Atherosclerotic Lesion Formation in Hypercholesterolemic Ldlr −/− /cdgI −/− and Ldlr −/− /p2y12 −/− Chimeric Mice
We next determined the effect of hematopoietic CDGI or P2Y12 deficiency on atherosclerosis in the aorta or aortic sinus of hypercholesterolemic mice. By morphometric analysis, we determined that lesions in the aortic sinus of Ldlr −/− / cdgI −/− chimeras were ≈42% smaller than those of Ldlr −/− / WT control chimeras (0.18±0.02 versus 0.31±0.05 mm 2 ;
P<0.001; Figures 3A and 3B ). Similarly, lesions in the aortic sinus of Ldlr −/− /p2y12 −/− chimeras were significantly smaller than those in controls (0.22±0.10 mm 2 ; P<0.01). Finally, Ldlr −/− /DKO chimeras had 48% smaller lesions compared with Ldlr −/− /WT controls (0.16±0.02 versus 0.31±0.05 mm 2 , P<0.001). Aortic root lesion size was similar between hypercholesterolemic Ldlr −/− /cdgI −/− , Ldlr −/− /p2y12 −/− , and Ldlr −/− / DKO chimeric mice, with no additive effect in mice lacking both CDGI and P2Y12. Atherosclerotic lesion development was also evaluated by en face analysis of the aortic arch and abdominal aorta. Analyses of the aortic arches showed a ≈2-fold reduction in lesion size for Ldlr −/− /cdgI −/− , Ldlr −/− /p2y12 −/− , and Ldlr −/− / DKO chimeras when compared with Ldlr −/− /WT chimeras (5.93±0.66%, 4.68±0.65%, 4.42±0.56% versus 9.26±1.21%; Figure 4A ). Similarly, atherosclerotic lesions in the abdominal aortas of Ldlr −/− /cdgI −/− , Ldlr −/− /p2y12 −/− , and Ldlr −/− / DKO chimeras were ≈2-fold smaller compared with Ldr −/− / WT chimeras (1.35±0.28%, 1.29±0.30%, 1.60±0.35% versus 3.48±0.80%; Figure 4B ). No additive effects were observed in double versus single knockout mice. Together, these results suggest a significant role for both CDGI and P2Y12 signaling in bone marrow-derived cells in promoting atherosclerosis throughout the arterial tree.
Reduced Platelet-Neutrophil Interactions in Blood from Hypercholesterolemic Ldlr −/− /cdgI −/− Mice
Activated platelets are known to form proinflammatory platelet-leukocyte aggregates in circulation, 7, 8 and these cellular aggregates are associated with increased atherosclerosis and acute coronary syndrome. 3 To test whether deficiency in CDGI or P2Y12 affects the formation of such aggregates, we measured platelet-neutrophil aggregates (PNAs), identified as GPIb + Ly6G + events by flow cytometric analysis, in blood from the above described Ldlr −/− chimeric mice. PNAs were significantly increased in Ldlr −/− /WT mice fed a HFD for 12 weeks when compared with mice on a normal diet ( Figure 5A ). In contrast, hypercholesterolemia did not induce any increase in circulating PNAs in Ldlr −/− /cdgI −/− , Ldlr −/− /p2y12 −/− , or Ldlr −/− /DKO mice. Consistent with this finding, plasma levels of platelet factor 4, a marker of systemic platelet activation, were significantly reduced in Ldlr −/− /cdgI −/− and Ldlr −/− / p2y12 −/− chimeras when compared with controls (Table) . Platelet-neutrophil adhesion was also investigated in blood from hypercholesterolemic mice perfused over collagen at a shear rate of 400 s −1 . In these experiments, αIIbβ3-mediated platelet aggregate formation was inhibited to better visualize PNA formation. Firm neutrophil adhesion to adherent platelets under flow was significantly reduced in Ldlr −/− /cdgI −/− and Ldlr −/− /DKO blood ( Figure 5B) . A trend to lower PNA formation was also observed in Ldlr −/− /p2y12 −/− blood. Together, these findings suggest that CDGI and P2Y12 may contribute to leukocyte recruitment into the developing plaque.
Decreased Inflammation and Plaque Remodeling in Hypercholesterolemic Ldlr −/− cdgI −/− Mice
We next investigated whether macrophage (anti-CD68) or neutrophil (anti-Ly6G) accumulation in areas of plaque development was affected in Ldlr −/− /cdgI −/− and Ldlr −/− /p2y12 −/− mice. In line with the decreased lesion area, we observed markedly reduced intimal macrophage abundance in the aortic roots of Ldlr −/− /cdgI −/− and Ldlr −/− /DKO chimeras when compared with Ldlr −/− /WT controls (0.10±0.007%, 0.10±0.006% versus 0.20±0.006%; Figures 6A and 6B and Figure II in the online-only Data Supplement). A less pronounced but significant reduction in macrophage content was observed in Ldlr −/− /p2y12 −/− chimeric mice. Similarly, we observed that the neutrophil content in the aortic sinus was significantly reduced in Ldlr −/− /cdgI −/− and Ldlr −/− /DKO chimeras. A small but insignificant reduction in neutrophil accumulation was also observed in the aortic sinus of Ldlr −/− /p2y12 −/− chimeras ( Figures 7A and 7B ). However, no marked differences in leukocyte numbers per lesion area were observed for any of the genotypes ( Figure III in the online-only Data Supplement), suggesting that loss of CDGI, and to a lesser extent P2Y12, may limit atherosclerotic lesion formation by impairing the recruitment of monocytes and neutrophils into the vessel wall at atherosusceptible sites ( Figures 6 and 7) .
In mice and humans, atherosclerotic plaque progression is associated with an increase in smooth muscle cell migration and proliferation within the subintima, where these cells produce and deposit extracellular matrix components, primarily collagen. Macrophages and neutrophils contain and release proteases such as elastase, cathepsin G, and myeloperoxidase that can degrade extracellular matrix proteins, resulting in plaque remodeling. Interestingly, collagen abundance was significantly greater in aortic sinus lesions of hypercholesterolemic Ldlr −/− /cdgI −/− and Ldlr −/− /DKO chimeric mice when compared with Ldlr −/− /WT controls (0.48±0.07% and 0.47±0.05% versus 0.27±0.01%; Figure 8 ), whereas no significant difference in collagen levels was observed between hypercholesterolemic Ldlr −/− /WT and Ldlr −/− /p2y12 −/− chimeric mice (Figure 8 ). As leukocyte densities were not significantly different between any groups of mice ( Figure III in the online-only Data Supplement), these findings suggest that, in addition to its role in leukocyte recruitment and atherogenesis, CDGI signaling may contribute to leukocyte activation and plaque destabilization.
Discussion
It is now widely accepted that platelets contribute to a proadhesive and proinflammatory environment during atherosclerosis. As shown by intravital microscopy, platelets adhere to the inflamed endothelium before lesions can be detected. 5 Once adherent and activated platelets can deposit chemokines on the luminal surface of the vessel wall. Activated platelets also express adhesion receptors important for the recruitment of leukocytes. Importantly, both leukocyte recruitment and atherosclerotic plaque formation were markedly reduced in thrombocytopenic mice or mice with select platelet adhesion defects. 5 However, the contribution of Rap1 signaling, a critical node in platelet activation to this process has not been established. To address this question, we studied atherosclerotic plaque development in Ldlr −/− chimeric mice lacking key regulators of platelet Rap1 signaling. We provide evidence that signaling by the Rap-GEF, CDGI, is critical in promoting both atherosclerotic plaque formation and remodeling in Ldlr −/− mice. We further demonstrate that plaque formation, but not composition, depends on signaling via the ADP receptor, P2Y12, an important pathway leading to Rap1 activation in platelets.
CDGI is an important regulator of Rap1 activity in murine platelets and neutrophils. Although our studies clearly show that CDGI signaling in hematopoietic cells is critical during atherosclerotic plaque development in mice, we cannot provide a conclusive answer for whether reduced plaque formation in Ldlr −/− /cdgI −/− chimeras is because of altered function of platelets, neutrophils, or both. However, for several reasons we think that CDGI signaling in platelets plays a critical role during plaque development. First, CDGI signaling is critical to αIIbβ3 integrin activation and platelet adhesion, important processes in atherosclerosis. Second, the CDGI-independent pathway to Rap1 activation and platelet adhesion requires signaling by P2Y12, a surface receptor that is not expressed on hematopoietic cell types other than platelets; plaque formation was also markedly impaired in Ldlr −/− /p2y12 −/− chimeras. Finally, both platelet activation and platelet-leukocyte aggregate formation were significantly reduced in both Ldlr −/− /cdgI −/− and Ldlr −/− /p2y12 −/− chimeras, providing a plausible explanation for the reduced accumulation of leukocytes in atheroprone areas of hypercholesterolemic mice. Future studies in mice lacking CDGI or the 2 Rap1 isoforms specifically in platelets or neutrophils will be required to clarify, on a cellular level, how this signaling pathway contributes to atherosclerotic lesion development, and whether the effects observed in Ldlr −/− /cdgI −/− mice are indeed caused by a defect in Rap1 signaling.
Interestingly, our studies also uncovered some interesting differences in plaque composition between Ldlr −/− /cdgI −/− and Ldlr −/− /p2y12 −/− mice, as plaques from Ldlr −/− /cdgI −/− chimeras were high in collagen content. It is well known that neutrophils secrete cytokines and proteases that result in (1) EC dysfunction and vascular permeability, (2) monocyte recruitment and foam cell formation, and (3) endothelial erosion and weakening of the fibrous cap. In humans, neutrophils are often found in rupture-prone plaques, ie, lesions with a large lipid core and low collagen content. 32 Thus, the increased collagen content in lesions of Ldlr −/− /cdgI −/− chimeras may, at least in part, be the result of impaired neutrophil activation, a conclusion that was not experimentally tested in this study. Future studies in mice with cell type-specific deletion of CDGI will be necessary to clarify these points.
A critical role for P2Y12 in atherosclerotic plaque development has been reported by several groups, using both genetic and pharmacological disruption of receptor function; however, the results using the P2Y12 inhibitor clopidogrel have been variable depending on the experimental conditions. Our results on the role of P2Y12 in atherosclerosis are in accordance with a recent publication by Li et al, 24 showing that deficiency of P2Y12 in apoE −/− mice fed a HFD for 20 weeks results in decreased atherosclerotic lesion formation. Both our study and that of Li et al 24 also document a significant reduction of plasma platelet factor 4 levels in P2Y12-deficient hypercholesterolemic mice, indicative of reduced platelet activation in these animals. In contrast, treatment of apoE −/− mice with the P2Y12 inhibitor clopidogrel bisulfate was associated with inconsistent results. Although 2 groups found significant protection from atherosclerosis in clopidogrel-treated mice, 27,28 other groups could not reproduce these findings. 29, 30 Pharmacological inhibition is more likely to give variable results than a genetic approach. We can only speculate that differences in the experimental conditions and the inhibitor dose may be responsible for the discrepant results. The genetic approach eliminates some of these potential inconsistencies and thus should be considered more definitive.
An interesting observation in our studies is that the atherosclerotic lesion area in Ldlr −/− /DKO chimeras was not statistically different from that in Ldlr −/− /cdgI −/− or Ldlr −/− /p2y12 −/− chimeric mice although a trend to smaller plaques was observed in the aortic sinus of DKO mice. Given that deficiency in CDGI or P2Y12 only partially inhibits Rap1-mediated platelet responses (Figure 1 ), one could have expected additive effects of deleting both molecules at the same time. It is important to remember, however, that synergistic activity by both pathways is required for Rap1 activation to occur in platelets that are activated with weak agonists, such as ADP (Figure 2 ), or threshold concentrations of strong agonists. 17, 23 Thus, our results suggest that only weak stimulation of platelets occurs at sites of plaque development, a conclusion that is consistent with the fact that the endothelial lining is intact at early stages of atherosclerosis. 33 Significant progress has been made in our understanding of the molecular mechanisms regulating plaque development and destabilization in experimental atherosclerosis. However, most of these new concepts have not been validated in humans, and translation of these findings into novel strategies to prevent atherosclerosis is lacking. Direct targeting of receptors critical for leukocyte or platelet adhesion, such as β2 and β3 integrins, is not a viable strategy, as these receptors are too important for the physiological function of these cells. Targeting of agonist receptors, such as G-protein-coupled receptors, would seem a better approach, but redundancy among these receptors may limit the effectiveness of such interventions. Based on our studies, CDGI represents a novel therapeutic target to limit atherosclerotic lesion development. Rap1 signaling is critical for integrin activation both in platelets and in neutrophils. CDGI is an important activator of Rap1, which operates downstream of most agonist receptors expressed on these cells. CDGI is important for the rapid inside-out activation of integrins, required for platelet adhesion under conditions of high shear stress; at lower shear stress, however, platelet adhesion is supported by CDGI-independent Rap1 signaling, mediated by PKC and P2Y12. Thus, CDGI signaling is particularly important for platelet adhesion in areas of high shear stress, such as found in the coronary arteries. Expression of CDGI is limited to few cell types, including platelets, neutrophils and neurons in certain areas in the brain. However, dogs 34 and humans 35 with loss-of-function mutations in CDGI are characterized by impaired function of platelets but not other cells. Based on these findings and our current work, we propose that inhibition of CDGI signaling may be a powerful approach to safely prevent atherosclerosis and atherothrombosis.
In summary, our findings reveal a critical role for the Rap1-GEF CDGI in promoting atherosclerotic plaque development in hypercholesterolemic Ldlr −/− mice. 
